The signing of these agreements is a critical step for Autonomix, indicating that the company is moving forward with its plans for the clinical trial. This progress is likely to be viewed positively by investors, as it demonstrates the company's commitment to advancing its treatment solutions and potentially capturing a significant share of the pancreatic cancer market. The initiation of patient enrollment would further solidify this positive outlook, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.